Analyzing the role of T-Dxd in DB06 HER2-low and HER2-ultralow advanced breast cancer

DESTINY-Breast06 validates T-DXd in HER2-low and pushes its use into the HER2-ultralow space. Drs. Pegram and Iyengar detail the trial design, the shift toward earlier use post–endocrine resistance, and how FDA labels now reflect this expanded spectrum of HER2 expression.